4 350

Cited 4 times in

HMG CoA Reductase Inhibitor Treatment Induces Dysglycemia in Renal Allograft Recipients

DC FieldValueLanguage
dc.contributor.author차봉수-
dc.contributor.author최은영-
dc.contributor.author허규하-
dc.contributor.author강은석-
dc.contributor.author권오빈-
dc.contributor.author김명수-
dc.contributor.author김유선-
dc.contributor.author안철우-
dc.contributor.author왕혜진-
dc.contributor.author이현철-
dc.contributor.author조용인-
dc.date.accessioned2015-01-06T16:27:21Z-
dc.date.available2015-01-06T16:27:21Z-
dc.date.issued2014-
dc.identifier.issn0041-1337-
dc.identifier.urihttps://ir.ymlib.yonsei.ac.kr/handle/22282913/98137-
dc.description.abstractBACKGROUND: Dysglycemia and dyslipidemia are important metabolic complications of organ transplantation. Statins are widely used to control dyslipidemia; however, long-term use of statins is related to diabetes mellitus (DM) and impaired fasting glucose (IFG). The aim of this study was to evaluate the influence of statins on the development of dysglycemia (IFG and/or DM) in renal allograft recipients. METHODS: A total of 394 patients without previously known DM or IFG who underwent kidney transplantation were enrolled. Patients were grouped into the two groups according to the use of statin (control, n=149; statin, n=245). The major statins used were fluvastatin (80 mg/d, n=134) and atorvastatin (20 mg/d, n=111). We compared the incidence of IFG or DM during the follow-up period. RESULTS: The incidence of IFG was higher in the statin group than that in the control group (28.6% vs. 8.7%, P<0.001). The incidence of dysglycemia was significantly higher in the statin group (40.0% vs. 15.4%, P=0.001). Time to development of dysglycemia after transplantation was shorter in the statin group than in the control group (38.8±29.7 vs. 47.2±23.3 months, P=0.002). Statin use was associated with an increased risk for dysglycemia after adjustment for age, sex, body mass index, hypertension, cholesterol levels, hepatitis C infection, and type of immunosuppressant (hazard ratio=3.08, 95% confidence interval=1.91-4.98). The dysglycemic effect was more profound in the patients who used atorvastatin than in those who used fluvastatin (hazard ratio=2.21, 95% confidence interval=1.02-4.76). CONCLUSION: Statin treatment is associated with an elevation in fasting plasma glucose and in the development of dysglycemia in renal allograft recipients.-
dc.description.statementOfResponsibilityopen-
dc.format.extent419~425-
dc.relation.isPartOfTransplantation-
dc.rightsCC BY-NC-ND 2.0 KR-
dc.rights.urihttps://creativecommons.org/licenses/by-nc-nd/2.0/kr/-
dc.titleHMG CoA Reductase Inhibitor Treatment Induces Dysglycemia in Renal Allograft Recipients-
dc.typeArticle-
dc.contributor.collegeCollege of Medicine (의과대학)-
dc.contributor.departmentDept. of Internal Medicine (내과학)-
dc.contributor.googleauthorEun Yeong Choe-
dc.contributor.googleauthorHye Jin Wang-
dc.contributor.googleauthorObin Kwon-
dc.contributor.googleauthorYongin Cho-
dc.contributor.googleauthorKyu Ha Huh-
dc.contributor.googleauthorMyoung Soo Kim-
dc.contributor.googleauthorYu Seun Kim-
dc.contributor.googleauthorChul Woo Ahn-
dc.contributor.googleauthorBong Soo Cha-
dc.contributor.googleauthorHyun Chul Lee-
dc.contributor.googleauthorEun Seok Kang-
dc.identifier.doi10.1097/01.TP.0000437427.04733.ad-
dc.admin.authorfalse-
dc.admin.mappingfalse-
dc.contributor.localIdA03996-
dc.contributor.localIdA04153-
dc.contributor.localIdA04344-
dc.contributor.localIdA00068-
dc.contributor.localIdA00234-
dc.contributor.localIdA00785-
dc.contributor.localIdA02270-
dc.contributor.localIdA02422-
dc.contributor.localIdA03301-
dc.contributor.localIdA03866-
dc.contributor.localIdA00424-
dc.relation.journalcodeJ02754-
dc.identifier.urlhttp://ovidsp.ovid.com/ovidweb.cgi?T=JS&CSC=Y&NEWS=N&PAGE=fulltext&AN=00007890-201402270-00010&LSLINK=80&D=ovft-
dc.contributor.alternativeNameCha, Bong Soo-
dc.contributor.alternativeNameChoe, Eun Yeong-
dc.contributor.alternativeNameHuh, Kyu Ha-
dc.contributor.alternativeNameKang, Eun Seok-
dc.contributor.alternativeNameKwon, O Bin-
dc.contributor.alternativeNameKim, Myoung Soo-
dc.contributor.alternativeNameKim, Yu Seun-
dc.contributor.alternativeNameAhn, Chul Woo-
dc.contributor.alternativeNameWang, Hye Jin-
dc.contributor.alternativeNameLee, Hyun Chul-
dc.contributor.alternativeNameCho, Yong In-
dc.contributor.affiliatedAuthorCha, Bong Soo-
dc.contributor.affiliatedAuthorChoe, Eun Yeong-
dc.contributor.affiliatedAuthorHuh, Kyu Ha-
dc.contributor.affiliatedAuthorKang, Eun Seok-
dc.contributor.affiliatedAuthorKwon, O Bin-
dc.contributor.affiliatedAuthorKim, Yu Seun-
dc.contributor.affiliatedAuthorAhn, Chul Woo-
dc.contributor.affiliatedAuthorWang, Hye Jin-
dc.contributor.affiliatedAuthorLee, Hyun Chul-
dc.contributor.affiliatedAuthorCho, Yong In-
dc.contributor.affiliatedAuthorKim, Myoung Soo-
dc.rights.accessRightsfree-
dc.citation.volume97-
dc.citation.number4-
dc.citation.startPage419-
dc.citation.endPage425-
dc.identifier.bibliographicCitationTransplantation, Vol.97(4) : 419-425, 2014-
Appears in Collections:
1. College of Medicine (의과대학) > Dept. of Internal Medicine (내과학교실) > 1. Journal Papers
1. College of Medicine (의과대학) > Dept. of Surgery (외과학교실) > 1. Journal Papers
1. College of Medicine (의과대학) > Yonsei Biomedical Research Center (연세의생명연구원) > 1. Journal Papers
1. College of Medicine (의과대학) > Dept. of Pharmacology (약리학교실) > 1. Journal Papers

qrcode

Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.